MarketBeat on MSN3d
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
The Motley Fool18d
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Novo Nordisk has tumbled on GLP-1 agonist ... Research from Grand View Research estimates GLP-1 agonist sales in North America could triple from $41 billion last year to $126 billion in 2030 ...
Yahoo Finance7d
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
Novo Nordisk is introducing a direct-to-patient ... Novo is slashing the cost for all doses of its glucagon-like peptide-receptor agonist (GLP-1RA) to $499 per month, a hefty discount to the ...